A doxycycline hydrochloride preparation and its preparation method and application
By adding sunscreen and oxygen barrier to the doxycycline hydrochloride preparation, the protective layer is formed, which solves the stability of doxycycline hydrochloride during centralized drinking water administration, and improves its stability under different dilution ratios and bioavailability significantly improve the therapeutic effect.
Patent Information
- Application Number
- CN202211532029.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-01
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2042-12-01
AI Technical Summary
When the existing doxycycline hydrochloride preparation is administered in centralized drinking water, the stability of the existing doxycycline hydrochloride is insufficient after dilution by water, resulting in a decrease in drug activity and is unable to effectively ensure the stability and therapeutic effect of the drug in clinical use.
By combining doxycycline hydrochloride, sunscreen (such as lemon oil) and oxygen barrier (such as Houttuynia cordata oil), doxycycline hydrochloride is protected from light and oxidation by forming a light barrier layer and oxygen barrier layer. A novel doxycycline hydrochloride preparation was prepared to ensure its stability at different dilution ratios.
It significantly improves the stability and bioavailability of doxycycline hydrochloride, enhances its therapeutic effect in centralized drinking water administration, reduces the clinical dose, and improves the therapeutic efficacy of poultry respiratory diseases.
Smart Images

Figure BDA0003974555880000071 
Figure BDA0003974555880000081 
Figure BDA0003974555880000091
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of pharmaceutical preparations, and specifically relates to a doxycycline hydrochloride preparation and a preparation method and application thereof. Background Art
[0002] Doxycycline Hydrochloride (Doxycycline Hyclate, also known as doxycycline hydrochloride) is a light yellow to yellow crystalline powder; odorless. It is used to treat Escherichia coli disease, salmonellosis, pasteurellosis caused by Gram-positive bacteria and Gram-negative bacteria in pigs and chickens, and respiratory diseases caused by mycoplasma. The phenolic hydroxyl, enol and amide groups contained in the structure of doxycycline hydrochloride are easily oxidized and hydrolyzed; doxycycline hydrochloride is unstable to light in water and easily forms isomers, causing its solution system to change color.
[0003] At present, veterinary drugs are mainly administered in groups in clinical practice, including mixing with feed and drinking water. Drinking water administration has the advantages of simple operation, low labor input, and group application, and has gradually been widely used by large-scale farms. In particular, doxycycline hydrochloride preparations are mainly administered through drinking water. Because of the administration of drinking water, the veterinary drug instructions show the dosage for free drinking water throughout the day. For example, doxycycline hydrochloride soluble powder, mixed drinking: 300 mg per 1L of water, chicken. However, in clinical use, it will not be administered through drinking water 24 hours a day, and concentrated administration is generally adopted for 3 to 6 hours. In this way, the total dosage remains unchanged, the amount of drinking water in 3 hours is reduced by 8 times, and the concentration of mixed drinking will increase by 8 times. For example, the concentration of mixed drinking at 3 hours will increase from 300 mg / L to 24h / 3h*300mg / L.
[0004] The doxycycline hydrochloride preparations currently sold in the domestic market include doxycycline hydrochloride tablets, doxycycline hydrochloride soluble powder, doxycycline hydrochloride injection, granules, uterine injections, and solutions reported in the literature. At present, researchers have prepared stable doxycycline hydrochloride preparations by adding complexing agents, antioxidants, preparing non-aqueous solvents, and internal and external packaging. Therefore, it is relatively stable when the commercial packaging form exists or when the packaging is tested. For example, CN 114028410A prepares a stable doxycycline hydrochloride soluble powder product by adding complexing agent EDTA2 sodium, antioxidant sodium citrate and citric acid; CN110075068A prepares a stable doxycycline hydrochloride soluble powder product by adding complexing agent dithiopropanol and antioxidant vitamin B. CN114028410A and CN 114732783A prepare stable solvent preparations by adding complexing agents citric acid and tartaric acid, antioxidants, preparing non-aqueous solvents, and flushing with nitrogen.
[0005] However, none of the prior art methods solves the problem of the stability of doxycycline hydrochloride during the drinking water period when it is diluted with water to different concentrations. Although the prior art ensures the stability of doxycycline hydrochloride by means of complexing agents, antioxidants, non-aqueous solvents, nitrogen protection and packaging, when the drug is administered in concentrated drinking water, the complexing agents, antioxidants and other means are diluted with water in a large proportion, and the concentration of the auxiliary materials is greatly reduced, thereby losing the protective effect, resulting in the photolysis and oxidation of doxycycline hydrochloride during concentrated drinking water. It can also be seen from the above invention that the stability of doxycycline hydrochloride requires a specific proportion of complexing agents, antioxidants and non-aqueous solvents to ensure the stability of doxycycline hydrochloride. Although CN 114732783A shows that the solution preparation of its invention is stable in drinking water administration for 24 hours, the concentrations of 300 mg / L and 600 mg / L designed in its experiment are for 24-hour drinking water administration, and this concentration will not be used clinically. Moreover, the invention book shows that the stability of doxycycline hydrochloride is ensured by the antioxidants, chelating agents and non-aqueous solvents selected by the invention within a certain concentration range. However, after being diluted with water in large proportions, the range of these excipients is greatly reduced and is far below the lower limit in the specification. The solution preparation of the invention is still stable in water after being diluted with water in large proportions. There is no theoretical support and it violates the common sense of pharmaceutical science.
[0006] Therefore, there is an urgent need for a doxycycline hydrochloride preparation that is stable when administered in concentrated drinking water to make up for the shortcomings of existing doxycycline hydrochloride preparations and to provide a highly effective drug for treating poultry respiratory diseases in veterinary clinics. Summary of the invention
[0007] In view of the problems and shortcomings in the prior art, the object of the present invention is to provide a doxycycline hydrochloride preparation and a preparation method and application thereof.
[0008] To achieve the purpose of the invention, the technical solution adopted by the present invention is as follows:
[0009] The first aspect of the present invention provides a doxycycline hydrochloride preparation, which is prepared from doxycycline hydrochloride, a sunscreen, an oxygen inhibitor and an adsorption carrier, wherein the sunscreen is a plant essential oil with ultraviolet absorption effect, and the oxygen inhibitor is an oily substance with antioxidant effect.
[0010] According to the above-mentioned doxycycline hydrochloride preparation, preferably, the density relationship between the sunscreen and the oxygen barrier is: sunscreen < oxygen barrier < water.
[0011] According to the above-mentioned doxycycline hydrochloride preparation, preferably, the sunscreen is at least one of marigold oil, tangerine oil, grapefruit essential oil, and lemon oil. More preferably, the sunscreen is lemon oil.
[0012] According to the above-mentioned doxycycline hydrochloride preparation, preferably, the antioxidant is at least one of VE oil, prickly ash oil, cinnamon oil, and houttuynia oil. More preferably, the antioxidant is houttuynia oil.
[0013] According to the above-mentioned doxycycline hydrochloride preparation, preferably, the limonene content in the lemon oil is ≥85%, and the total volatile oil in the houttuynia cordata oil is ≥80%.
[0014] According to the above-mentioned doxycycline hydrochloride preparation, preferably, the mass ratio of the doxycycline hydrochloride, sunscreen, oxygen barrier and adsorption carrier is 1: (0.1-0.5): (0.1-0.5): (1-3). More preferably, the mass ratio of the doxycycline hydrochloride, sunscreen, oxygen barrier and adsorption carrier is 1: (0.1-0.3): (0.1-0.3): (1-2).
[0015] According to the above-mentioned doxycycline hydrochloride preparation, preferably, the adsorption carrier is at least one of β-cyclodextrin, hydroxypropyl β-cyclodextrin, maltodextrin, and water-soluble starch.
[0016] The second aspect of the present invention provides a method for preparing the doxycycline hydrochloride preparation according to the first aspect, comprising the following steps:
[0017] (1) dissolving a sunscreen and an oxygen barrier in a solvent to obtain a solution a;
[0018] (2) using an adsorption carrier to solidify and adsorb solution a to obtain powder b; and uniformly mixing doxycycline hydrochloride and powder B to obtain a doxycycline hydrochloride preparation.
[0019] According to the above preparation method, preferably, the solvent is ethanol. More preferably, the amount of the solvent is 1.5 to 3 times the total mass of the sunscreen and the oxygen barrier.
[0020] According to the above preparation method, preferably, the solidification adsorption in step (2) is carried out in a fluidized bed. The specific operation of solidification adsorption is: start the fluidized bed, set the air inlet temperature and the air outlet temperature, add the adsorption carrier into the fluidized bed, and then add solution a into the fluidized bed for solidification. More preferably, the air inlet temperature of the fluidized bed is 105°C and the air outlet temperature is 55°C.
[0021] The third aspect of the present invention provides the use of the doxycycline hydrochloride preparation described in the first aspect in the preparation of veterinary drugs. More preferably, the drug is a drug for treating respiratory diseases.
[0022] Compared with the prior art, the technical effects achieved by the present invention are:
[0023] (1) The present invention utilizes a preparation method to combine conventional plant essential oils such as lemon oil and houttuynia cordata oil with doxycycline hydrochloride to prepare a new preparation. Since the densities of the sunscreen, the oxygen barrier and water are different (sunscreen < oxygen barrier < water) and the three are immiscible, the new preparation of the present invention can form three interface systems when used for centralized drinking water administration, namely, an upper sunscreen system, a middle oxygen barrier system and a lower doxycycline hydrochloride aqueous solution system; moreover, the upper sunscreen system can consume ultraviolet rays to achieve a sunscreen effect, which can effectively prevent the doxycycline hydrochloride in the lower aqueous solution system from generating isomers due to light; the oxygen barrier system can combine with external oxygen and oxygen in water to achieve an oxygen barrier and anti-oxidation effect, which can effectively prevent the doxycycline hydrochloride in the lower aqueous solution system from oxidative hydrolysis. Therefore, under the protection of the sunscreen layer and the oxygen barrier layer, the stability of the lower doxycycline hydrochloride aqueous solution is greatly improved, thereby solving the technical problem that doxycycline hydrochloride is easily oxidized and hydrolyzed and is unstable to light when administered in centralized drinking water.
[0024] (2) The lemon oil system contains rich limonene, which can consume ultraviolet rays and play a good sun-shielding role; Houttuynia cordata oil contains a large amount of houttuynia cordata flavonoids, which can combine with external oxygen and oxygen in water to play a good oxygen-blocking and antioxidant role. Therefore, the sunscreen is preferably lemon oil, and the oxygen inhibitor is preferably houttuynia cordata oil.
[0025] (3) Existing preparations all use preparation and packaging methods to improve the stability of doxycycline hydrochloride preparations, ignoring the environment when doxycycline hydrochloride is soluble in drinking water. When it is administered in drinking water, the active ingredients in the doxycycline hydrochloride preparation that originally act as stabilizers are diluted by a large proportion of water, and the proportion is destroyed, reducing or losing the protective effect of doxycycline hydrochloride. However, the sunscreen and oxygen barrier system in the doxycycline hydrochloride preparation of the present invention are not affected by water dilution, and a sunscreen layer and an oxygen barrier layer are formed at any dilution ratio, which can provide effective protection for doxycycline hydrochloride. Therefore, the doxycycline hydrochloride preparation of the present invention greatly improves the stability of doxycycline hydrochloride at different dilution concentrations when it is administered in a concentrated manner, ensuring that a sufficient amount of doxycycline hydrochloride enters the body of poultry through drinking water to achieve an effective treatment effect.
[0026] (4) When the doxycycline hydrochloride preparation prepared by the present invention is administered in drinking water, the stability of doxycycline hydrochloride in water is greatly improved compared with the existing preparations at different dilution ratios. Moreover, pharmacokinetic tests and efficacy tests also show that the bioavailability and therapeutic effect of the present invention in animals are better than those of the existing preparations, which also proves that after solving the problem of doxycycline hydrochloride stability in water, the effect of the present invention is significantly improved compared with the existing preparations, and the clinical dosage can be reduced in clinical application, thereby improving the therapeutic effect of poultry respiratory diseases. DETAILED DESCRIPTION
[0027] The present invention is further described in detail below through specific examples, but the scope of the present invention is not limited thereto.
[0028] Example 1: Sunscreen screening experiment
[0029] In order to study the effects of different types of sunscreens on the stability of doxycycline hydrochloride, the inventors carried out Examples 1-1 to 1-5.
[0030] Example 1-1:
[0031] 1.2 g of doxycycline hydrochloride was dissolved in 1 L of water to obtain a doxycycline hydrochloride aqueous solution with a concentration of 1.2 g / L. A sunscreen, lemon oil, was added to the doxycycline hydrochloride aqueous solution in a mass ratio of doxycycline hydrochloride to the sunscreen of 1:0.3. The solution was then placed in a room temperature environment with a light intensity of 4500 illuminance. After 6 hours, the changes in the doxycycline hydrochloride aqueous solution were observed. The results are shown in Table 1.
[0032] The contents of Examples 1-2 to 1-4 are substantially the same as those of Example 1-1, except that different sunscreens are used. The sunscreens used in Examples 1-2 to 1-4 are marigold oil, tangerine oil, and grapefruit essential oil, respectively. The contents of Example 1-5 are substantially the same as those of Example 1-1, except that no sunscreen is added, i.e., a doxycycline hydrochloride aqueous solution having a configuration concentration of 1.2 g / L is directly placed in an environment having a light intensity of 4500 illuminance for 6 hours.
[0033] Table 1 Sunscreen agent screening test results
[0034] Example Sunscreen Changes of doxycycline hydrochloride aqueous solution after 6 hours Example 1-1 Lemon Oil There is no turbidity on the liquid surface, and the color is equivalent to the yellow standard No. 1 colorimetric solution Example 1-2 Marigold Oil A little turbidity appears on the liquid surface, and the color is similar to the yellow standard No. 2 colorimetric solution. Examples 1-3 Tangerine Oil The liquid surface produces more turbidity, and the color is darker than the yellow standard No. 2 colorimetric solution Examples 1-4 Grapefruit essential oil A lot of turbidity is produced on the liquid surface, and the color is similar to the yellow standard No. 4 colorimetric solution Examples 1-5 / A large amount of red turbidity is produced on the liquid surface, and the color is darker than the yellow standard No. 4 colorimetric solution.
[0035] As shown in Table 1, when lemon oil is used as a sunscreen, the formed sunscreen layer has the best light protection effect on doxycycline hydrochloride dissolved in tap water. After being placed in an environment with a light intensity of 4500 illumination for 6 hours, no turbidity is produced on the liquid surface, and the doxycycline hydrochloride aqueous solution is light yellow and clear. Therefore, the sunscreen is preferably lemon oil.
[0036] Example 2: Oxygen inhibitor screening experiment
[0037] In order to study the effects of different types of antioxidants on the stability of doxycycline hydrochloride, the inventors conducted Examples 2-1 to 2-5.
[0038] Example 2-1:
[0039] 1.2 g of doxycycline hydrochloride was dissolved in 1 L of water to obtain a doxycycline hydrochloride aqueous solution with a concentration of 1.2 g / L. An antioxidant, Houttuynia cordata oil, was added to the doxycycline hydrochloride aqueous solution. The mass ratio of doxycycline hydrochloride to the antioxidant was 1:0.3. The solution was then placed at room temperature. After 6 hours, the dissolved oxygen (DO) value in the doxycycline hydrochloride aqueous solution was observed. The results are shown in Table 2.
[0040] The contents of Examples 2-2 to 2-4 are basically the same as those of Example 2-1, except that different antioxidants are used. The antioxidants used in Examples 2-2 to 2-4 are VE oil, prickly ash oil, and cinnamon oil, respectively. The contents of Example 2-5 are basically the same as those of Example 2-1, except that no antioxidant is added, that is, the doxycycline hydrochloride aqueous solution with a concentration of 1.2 g / L is directly placed at room temperature for 6 hours.
[0041] Table 2 Oxygen inhibitor screening test results
[0042] Example Oxygen Inhibitor DO(mg / L) Example 2-1 Houttuynia cordata oil 2.2 Example 2-2 VE Oil 5.5 Example 2-3 Sichuan pepper oil 6.3 Embodiment 2-4 Cinnamomum cassia oil 5.2 Embodiment 2-5 / 10.3
[0043] As shown in Table 2, when Houttuynia cordata oil is used as an oxygen barrier, the dissolved oxygen content in the doxycycline hydrochloride aqueous solution is the lowest, only 2.2 mg / L, after being placed at room temperature for 6 hours. This shows that Houttuynia cordata oil has the best oxygen barrier effect and can block oxygen from entering the doxycycline hydrochloride aqueous solution.
[0044] Example 3: Adsorption carrier screening experiment
[0045] In order to study the effects of different types of adsorption carriers, the inventors carried out Examples 3-1 to 3-4.
[0046] Example 3-1:
[0047] 6g of sunscreen and 6g of antioxidant are dissolved in 24g of anhydrous ethanol to obtain solution a, wherein the sunscreen is lemon oil and the antioxidant is houttuynia oil; 40g of adsorption carrier and solution a are added into a fluidized bed, and solution a is solidified and adsorbed to obtain powder b, wherein the adsorption carrier is β-cyclodextrin.
[0048] The contents of Example 3-2 to Example 3-4 are basically the same as Example 3-1, except that different adsorption carriers are used. The adsorption carriers used in Example 3-2 to Example 3-4 are water-soluble starch, maltodextrin, and hydroxypropyl β-cyclodextrin, respectively.
[0049] The repose angles (θ) of the powders b prepared in Examples 3-1 to 3-5 were measured respectively to analyze the effects of different adsorption carriers on the fluidity of the powders b. The results are shown in Table 3.
[0050] Table 3 Adsorption carrier screening experimental results
[0051] Example Adsorption carrier θ(°) Example 3-1 β-Cyclodextrin 26 Example 3-2 Water-soluble starch 40 Example 3-3 Maltodextrin 35 Embodiment 3-4 Hydroxypropyl β-cyclodextrin 30
[0052] As shown in Table 3, when β-cyclodextrin is used as the adsorption carrier, the carrier powder b has the smallest repose angle (26°) after curing and the best fluidity. Although other adsorption carriers can produce a curing effect, they have a larger repose angle and poor fluidity. When the powder repose angle is greater than 30°, the fluidity cannot meet the normal production requirements. Therefore, the adsorption carrier is preferably β-cyclodextrin.
[0053] Example 4: Sunscreen agent - lemon oil dosage screening experiment
[0054] In order to study the effect of the amount of sunscreen lemon oil on the stability of doxycycline hydrochloride preparations, the inventors carried out Examples 4-1 to 4-7.
[0055] Example 4-1:
[0056] A doxycycline hydrochloride preparation is prepared from doxycycline hydrochloride (1.2 g), a sunscreen, an oxygen inhibitor (0.36 g) and an adsorption carrier (2.4 g), wherein the sunscreen is lemon oil, the oxygen inhibitor is houttuynia cordata oil, the adsorption carrier is β-cyclodextrin, and the mass ratio of doxycycline hydrochloride to lemon oil is 1:0.05.
[0057] The preparation method of the above-mentioned doxycycline hydrochloride preparation is as follows:
[0058] (1) According to the composition of the above-mentioned doxycycline hydrochloride preparation, weigh doxycycline hydrochloride, a sunscreen, an oxygen inhibitor and an adsorption carrier and set aside.
[0059] (2) dissolving the sunscreen and the oxygen barrier in anhydrous ethanol to obtain a solution a;
[0060] (3) using an adsorption carrier to solidify and adsorb solution a to obtain powder b; and uniformly mixing doxycycline hydrochloride and powder b to obtain a doxycycline hydrochloride preparation.
[0061] The contents of Examples 4-2 to 4-7 are substantially the same as those of Example 4-1, except that the mass ratios of doxycycline hydrochloride to lemon oil are different. The mass ratios of doxycycline hydrochloride to lemon oil in Examples 4-2 to 4-7 are 1:0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, and 1:0.6, respectively.
[0062] The doxycycline hydrochloride preparations prepared in Examples 4-1 to 4-7 were added to 1 L of water, stirred to dissolve, and then placed in a room temperature environment with a light intensity of 4500 illuminance. After 6 hours, the changes in the lower layer of the doxycycline hydrochloride aqueous solution (the concentration of doxycycline hydrochloride in the doxycycline hydrochloride aqueous solution was 1.2 g / L) were observed. The results are shown in Table 4.
[0063] Table 4 Sunscreen dosage screening test results
[0064]
[0065] As shown in Table 4, when the mass ratio of doxycycline hydrochloride to lemon oil is lower than 1:0.1, after 6 hours, the doxycycline hydrochloride solution is clear but dark in color, which is equivalent to the yellow standard colorimetric solution No. 5, indicating that doxycycline hydrochloride is greatly affected by photolysis. As the amount of lemon oil increases, the color of the doxycycline hydrochloride solution gradually becomes lighter, but when the ratio increases to 1:(0.3-0.6), the solution color is close to the yellow standard colorimetric solution No. 1, indicating that doxycycline hydrochloride is less affected by photolysis. Considering the comprehensive stability effect and cost factors, the mass ratio of doxycycline hydrochloride to lemon oil is preferably 1:(0.3-0.6), and more preferably 1:0.3.
[0066] Example 5: Oxidation inhibitor - Houttuynia cordata oil dosage screening experiment
[0067] In order to study the effect of the amount of sunscreen Houttuynia cordata oil on the stability of doxycycline hydrochloride preparations, the inventors carried out Examples 5-1 to 5-6.
[0068] Example 5-1:
[0069] A doxycycline hydrochloride preparation is prepared from doxycycline hydrochloride (1.2 g), a sunscreen (0.36 g), an oxygen inhibitor and an adsorption carrier (2.4 g), wherein the sunscreen is lemon oil, the oxygen inhibitor is houttuynia cordata oil, the adsorption carrier is β-cyclodextrin, the mass ratio of doxycycline hydrochloride to lemon oil is 1:0.3, and the mass ratio of doxycycline hydrochloride to houttuynia cordata oil is 1:0.05.
[0070] The preparation method of the above-mentioned doxycycline hydrochloride preparation is as follows:
[0071] (1) According to the composition of the above-mentioned doxycycline hydrochloride preparation, weigh doxycycline hydrochloride, a sunscreen, an oxygen barrier and an adsorption carrier and set aside.
[0072] (2) dissolving the sunscreen and the oxygen barrier in anhydrous ethanol to obtain a solution a;
[0073] (3) using an adsorption carrier to solidify and adsorb solution a to obtain powder b; and uniformly mixing doxycycline hydrochloride and powder b to obtain a doxycycline hydrochloride preparation.
[0074] The contents of Examples 5-2 to 5-6 are substantially the same as those of Example 5-1, except that the mass ratios of doxycycline hydrochloride to houttuynia cordata oil are different. The mass ratios of doxycycline hydrochloride to houttuynia cordata oil in Examples 5-2 to 5-6 are 1:0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, and 1:0.6, respectively.
[0075] The doxycycline hydrochloride preparations prepared in Examples 5-1 to 5-6 were added to 1 L of water, stirred to dissolve, and then placed at room temperature. After 6 hours, the dissolved oxygen (DO) value in the lower layer of the doxycycline hydrochloride aqueous solution (the concentration of doxycycline hydrochloride in the solution was 1.2 g / L) was observed. The results are shown in Table 5.
[0076] Table 5 Results of the screening experiment on the dosage of oxygen inhibitor
[0077]
[0078] As shown in Table 5, when the mass ratio of doxycycline hydrochloride to houttuynia oil is lower than 1:0.1, the dissolved oxygen content in the doxycycline hydrochloride aqueous solution is high. As the amount of houttuynia oil increases, the dissolved oxygen content in the doxycycline hydrochloride aqueous solution gradually decreases. However, when the mass ratio of doxycycline hydrochloride to houttuynia oil is 1:0.3, the dissolved oxygen content in the doxycycline hydrochloride aqueous solution is reduced to 2.2 mg / L. When the amount of houttuynia oil is further increased, the dissolved oxygen content in the doxycycline hydrochloride aqueous solution does not change significantly. Considering the comprehensive stabilization effect and cost factors, the mass ratio of doxycycline hydrochloride to houttuynia oil is preferably 1:(0.1-0.5), and more preferably 1:0.3.
[0079] Example 6: Adsorption carrier - β-cyclodextrin dosage screening experiment
[0080] In order to study the effect of the amount of sunscreen Houttuynia cordata oil on the stability of doxycycline hydrochloride preparations, the inventors carried out Examples 6-1 to 6-5.
[0081] Example 6-1:
[0082] A doxycycline hydrochloride preparation is prepared from doxycycline hydrochloride (1.2 g), a sunscreen, an oxygen inhibitor and an adsorption carrier, wherein the sunscreen is lemon oil, the oxygen inhibitor is houttuynia cordata oil, the adsorption carrier is β-cyclodextrin, the mass ratio of doxycycline hydrochloride to lemon oil is 1:0.3, the mass ratio of doxycycline hydrochloride to houttuynia cordata oil is 1:0.3, and the mass ratio of doxycycline hydrochloride to β-cyclodextrin is 1:0.5.
[0083] The preparation method of the above-mentioned doxycycline hydrochloride preparation is as follows:
[0084] (1) According to the composition of the above-mentioned doxycycline hydrochloride preparation, weigh doxycycline hydrochloride, a sunscreen, an oxygen barrier and an adsorption carrier and set aside.
[0085] (2) dissolving the sunscreen and the oxygen barrier in anhydrous ethanol to obtain a solution a;
[0086] (3) using an adsorption carrier to solidify and adsorb solution a to obtain powder b; and uniformly mixing doxycycline hydrochloride and powder b to obtain a doxycycline hydrochloride preparation.
[0087] The contents of Examples 6-2 to 6-5 are substantially the same as those of Example 6-1, except that the mass ratios of doxycycline hydrochloride to houttuynia oil are different. The mass ratios of doxycycline hydrochloride to houttuynia oil in Examples 5-2 to 5-7 are 1:1, 1:1.5, 1:2, 1:2.5, 1:3, and 1:3.5, respectively.
[0088] The angles of repose (θ) of the doxycycline hydrochloride preparations prepared in Examples 6-1 to 6-5 were measured to analyze the effects of different amounts of adsorption carriers on the fluidity of the doxycycline hydrochloride preparations. The results are shown in Table 6.
[0089] Table 6 Adsorption carrier dosage screening experimental results
[0090]
[0091] It can be seen from Table 6 that when the amount of β-cyclodextrin is small, the angle of repose of the prepared doxycycline hydrochloride preparation is large and the fluidity is poor. As the amount of β-cyclodextrin increases, the angle of repose of the doxycycline hydrochloride preparation becomes smaller and the fluidity becomes better and better. When the mass ratio of doxycycline hydrochloride to Houttuynia cordata oil adsorption carrier is 1:2, the angle of repose of the doxycycline hydrochloride preparation reaches 25°. When the amount of β-cyclodextrin is further increased, the angle of repose does not change significantly. Considering the comprehensive flow effect and cost factors, the mass ratio of doxycycline hydrochloride to β-cyclodextrin is preferably 1: (1-3), and more preferably 1:2.
[0092] Embodiment 7:
[0093] A doxycycline hydrochloride preparation is prepared from doxycycline hydrochloride (1.2 g), a sunscreen, an oxygen inhibitor and an adsorption carrier, wherein the sunscreen is marigold oil, the oxygen inhibitor is houttuynia oil, the adsorption carrier is β-cyclodextrin, the mass ratio of doxycycline hydrochloride to marigold oil is 1:0.3, the mass ratio of doxycycline hydrochloride to houttuynia oil is 1:0.3, and the mass ratio of doxycycline hydrochloride to β-cyclodextrin is 1:2.
[0094] The preparation method of the above doxycycline hydrochloride preparation is the same as that of Example 4-1.
[0095] The angle of repose of the doxycycline hydrochloride preparation prepared in this example was measured. At the same time, the doxycycline hydrochloride preparation prepared in this example was dissolved in 1 L of water, stirred and dissolved, and placed in a room temperature environment with a light intensity of 4500 illuminance. After 6 hours, the changes in the lower layer of the doxycycline hydrochloride aqueous solution (the concentration of doxycycline hydrochloride in the doxycycline hydrochloride aqueous solution was 1.2 g / L) were observed.
[0096] The angle of repose of the doxycycline hydrochloride preparation powder prepared in this example is 27°. Moreover, it is found through observation that after 6 hours, the doxycycline hydrochloride solution is clear and its color is equivalent to the yellow standard No. 2 colorimetric solution; after 6 hours, the dissolved oxygen content in the lower layer of the doxycycline hydrochloride aqueous solution is 2.3 mg / L.
[0097] Embodiment 8:
[0098] A doxycycline hydrochloride preparation is prepared from doxycycline hydrochloride (1.2 g), a sunscreen, an oxygen inhibitor and an adsorption carrier, wherein the sunscreen is tangerine oil, the oxygen inhibitor is houttuynia oil, the adsorption carrier is β-cyclodextrin, the mass ratio of doxycycline hydrochloride to tangerine oil is 1:0.3, the mass ratio of doxycycline hydrochloride to houttuynia oil is 1:0.3, and the mass ratio of doxycycline hydrochloride to β-cyclodextrin is 1:2.
[0099] The preparation method of the above doxycycline hydrochloride preparation is the same as that of Example 4-1.
[0100] The angle of repose of the doxycycline hydrochloride preparation prepared in this example was measured. At the same time, the doxycycline hydrochloride preparation prepared in this example was dissolved in 1 L of water, stirred and dissolved, and placed in a room temperature environment with a light intensity of 4500 illuminance. After 6 hours, the changes in the lower layer of doxycycline hydrochloride aqueous solution (the concentration of doxycycline hydrochloride in the doxycycline hydrochloride aqueous solution was 1.2 g / L) were observed, and the DO value of the lower layer of doxycycline hydrochloride aqueous solution was detected.
[0101] The angle of repose of the doxycycline hydrochloride preparation powder prepared in this example is 28°. In addition, it is found through observation that after 6 hours, the doxycycline hydrochloride solution is clear and its color is darker than the yellow standard No. 2 colorimetric solution; after 6 hours, the oxygen content in the solution is 2.5 mg / L.
[0102] Embodiment 9:
[0103] A doxycycline hydrochloride preparation is prepared from doxycycline hydrochloride (1.2 g), a sunscreen, an oxygen inhibitor and an adsorption carrier, wherein the sunscreen is marigold oil, the oxygen inhibitor is cinnamon oil, the adsorption carrier is beta-cyclodextrin, the mass ratio of doxycycline hydrochloride to marigold oil is 1:0.3, the mass ratio of doxycycline hydrochloride to cinnamon oil is 1:0.3, and the mass ratio of doxycycline hydrochloride to beta-cyclodextrin is 1:2.
[0104] The preparation method of the above doxycycline hydrochloride preparation is the same as that of Example 4-1.
[0105] The angle of repose of the doxycycline hydrochloride preparation prepared in this example was measured. At the same time, the doxycycline hydrochloride preparation prepared in this example was dissolved in 1 L of water, stirred and dissolved, and placed in a room temperature environment with a light intensity of 4500 illuminance. After 6 hours, the changes in the lower layer of doxycycline hydrochloride aqueous solution (the concentration of doxycycline hydrochloride in the doxycycline hydrochloride aqueous solution was 1.2 g / L) were observed, and the DO value of the lower layer of doxycycline hydrochloride aqueous solution was detected.
[0106] The angle of repose of the doxycycline hydrochloride preparation powder prepared in this example is 29°, and it is observed that after 6 hours, the doxycycline hydrochloride solution is clear and transparent, and its color is equivalent to the yellow standard colorimetric solution No. 2. After 6 hours, the oxygen content in the solution is 4.9 mg / L.
[0107] Embodiment 10:
[0108] A doxycycline hydrochloride preparation is prepared from doxycycline hydrochloride (1.2 g), a sunscreen, an oxygen inhibitor and an adsorption carrier, wherein the sunscreen is tangerine oil, the oxygen inhibitor is cinnamon oil, the adsorption carrier is β-cyclodextrin, the mass ratio of doxycycline hydrochloride to tangerine oil is 1:0.3, the mass ratio of doxycycline hydrochloride to cinnamon oil is 1:0.3, and the mass ratio of doxycycline hydrochloride to β-cyclodextrin is 1:2.
[0109] The preparation method of the above doxycycline hydrochloride preparation is the same as that of Example 4-1.
[0110] The angle of repose of the doxycycline hydrochloride preparation prepared in this example was measured. At the same time, the doxycycline hydrochloride preparation prepared in this example was dissolved in 1 L of water, stirred and dissolved, and placed in a room temperature environment with a light intensity of 4500 illuminance. After 6 hours, the changes in the lower layer of doxycycline hydrochloride aqueous solution (the concentration of doxycycline hydrochloride in the doxycycline hydrochloride aqueous solution was 1.2 g / L) were observed, and the DO value of the lower layer of doxycycline hydrochloride aqueous solution was detected.
[0111] The angle of repose of the doxycycline hydrochloride preparation powder prepared in this embodiment is 27°, and it is observed that after 6 hours, the doxycycline hydrochloride solution is clear and its color is darker than the yellow standard No. 2 colorimetric solution; after 6 hours, the oxygen content in the solution is 5.1 mg / L.
[0112] Embodiment 11:
[0113] A doxycycline hydrochloride preparation is prepared from doxycycline hydrochloride (1.2 g), a sunscreen, an oxygen inhibitor and an adsorption carrier, wherein the sunscreen is lemon oil, the oxygen inhibitor is prickly ash oil, the adsorption carrier is β-cyclodextrin, the mass ratio of doxycycline hydrochloride to lemon oil is 1:0.3, the mass ratio of doxycycline hydrochloride to prickly ash oil is 1:0.3, and the mass ratio of doxycycline hydrochloride to β-cyclodextrin is 1:2.
[0114] The preparation method of the above doxycycline hydrochloride preparation is the same as that of Example 4-1.
[0115] The angle of repose of the doxycycline hydrochloride preparation prepared in this example was measured. At the same time, the doxycycline hydrochloride preparation prepared in this example was dissolved in 1 L of water, stirred and dissolved, and placed in a room temperature environment with a light intensity of 4500 illuminance. After 6 hours, the changes in the lower layer of doxycycline hydrochloride aqueous solution (the concentration of doxycycline hydrochloride in the doxycycline hydrochloride aqueous solution was 1.2 g / L) were observed, and the DO value of the lower layer of doxycycline hydrochloride aqueous solution was detected.
[0116] The angle of repose of the doxycycline hydrochloride preparation powder prepared in this example is 26°. In addition, it is found through observation that after 6 hours, the doxycycline hydrochloride solution is clear and its color is slightly darker than the yellow standard No. 1 colorimetric solution; after 6 hours, the oxygen content in the solution is 6.0 mg / L.
[0117] Example 12: Performance test of the doxycycline hydrochloride preparation prepared by the present invention
[0118] 1. Centralized drinking water stability test:
[0119] Taking the doxycycline hydrochloride preparation prepared in Example 4-4 of the present invention as an example, the centralized drinking water stability of the doxycycline hydrochloride preparation was verified. At the same time, the present invention uses the commercially available batch of doxycycline hydrochloride soluble powder (batch number: 2201013) of Shandong ** Pharmaceutical Co., Ltd. and doxycycline hydrochloride non-aqueous solution (doxycycline hydrochloride non-aqueous solution is prepared according to the preparation method recorded in CN 114732783A) as a comparison.
[0120] The specific operation of the centralized drinking water stability test experiment is as follows: add the experimental doxycycline hydrochloride preparation to water, and prepare solutions with doxycycline hydrochloride concentrations of 1200 mg / L and 2400 mg / L respectively (according to the 2020 edition of the Veterinary Pharmacopoeia, the doxycycline hydrochloride drinking water dose is 300 mg / L (doxycycline), and the clinical centralized drinking water is converted for 3h and 6h. The concentration of doxycycline hydrochloride aqueous solution is selected as 2400 mg / L and 1200 mg / L respectively), and the solution is placed in an environment with a light condition of 4500 illumination and a temperature of 25°C. According to the detection method of doxycycline hydrochloride soluble powder in the 2020 edition of the Chinese Veterinary Pharmacopoeia, the content change in the doxycycline hydrochloride aqueous solution is detected. The doxycycline hydrochloride content in the solution at different placement times (0h, 1h, 2h, 3h) is detected, and the decomposition rate of doxycycline hydrochloride is calculated. The test results are shown in Tables 7 and 8.
[0121] Chromatographic conditions for doxycycline hydrochloride detection: octadecylsilane bonded silica gel as filler (pH value applicable range should be greater than 9), acetate buffer (0.25 mol / L ammonium acetate-0.1 mol / L disodium ethylenediaminetetraacetate-triethylamine (100:10:1), pH value adjusted to 8.8 with glacial acetic acid or ammonia water)-acetonitrile (85:15) as mobile phase, column temperature 35°C, detection wavelength 280nm, flow rate 1.0ml / min, injection volume 20μL.
[0122] Table 7 Centralized drinking water 3h (2400mg / L) stability results
[0123]
[0124] Table 8 Centralized drinking water 6h (1200mg / L) stability results
[0125]
[0126] As can be seen from Tables 7 and 8, and from the test results of Tables 6 and 7, the stability of doxycycline hydrochloride in centralized drinking water is: Implementation 4-4> Example 5-3> Implementation 4-3> solution non-aqueous preparation> commercially available soluble powder. It can be seen that the centralized drinking water stability of the doxycycline hydrochloride preparation prepared by the present invention is significantly better than the stability of the existing preparation products, and a good expected result is achieved.
[0127] 2. Pharmacokinetic test
[0128] The specific operation of the pharmacokinetic test is as follows: 30 white-feathered broilers are randomly divided into 3 groups, namely experimental group 1, experimental group 2 and experimental group 3, each group of 10 (half male and half female), in terms of doxycycline hydrochloride, the three groups of group dosages are 1200 mg / L, and the administration method is concentrated 6h drinking water administration. The medicine used in experimental group I is the doxycycline hydrochloride preparation prepared by Example 6-4 of the present invention, the medicine used in experimental group II is the commercially available batch of Shandong ** Pharmaceutical Co., Ltd. doxycycline hydrochloride soluble powder (lot number: 2201013), and the medicine used in experimental group III is a non-aqueous preparation doxycycline hydrochloride solution (doxycycline hydrochloride non-aqueous solution is prepared according to the preparation method of CN 114732783A document record).
[0129] The three groups of experimental animals were fasted for 12 h before administration, and about 1.1 mL of blood was collected from the right subwing vein at 10 min, 30 min, 45 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 7 h, 10 h, 12 h, 24 h, 36 h, 48 h, 60 h, 72 h, 84 h, and 96 h after administration. After anticoagulation with sodium heparin, the blood was centrifuged at 4 000 r / min for 10 min to separate the plasma samples, which were stored in a -20°C refrigerator.
[0130] Accurately measure 500 μL of plasma, add 300 μL of 0.1 g / mL ascorbic acid solution and 200 μL of 18% perchloric acid solution, vortex for 3 minutes, centrifuge at 12000 r / min for 15 minutes, filter the supernatant through a 0.22 μm handheld syringe filter, place it in an injection bottle, and perform high performance liquid chromatography to detect the content of doxycycline hydrochloride. Calculate the pharmacokinetic parameter T based on the test results max , C max , T 1 / 2Ka and AUC 0-∞ The specific results are shown in Table 9.
[0131] Table 9 Pharmacokinetic parameters of doxycycline after drinking water in Example 2, Comparative Example 1, and Comparative Example 2
[0132]
[0133] As shown in Table 9, the pharmacokinetic test results show that the pharmacokinetic parameters Tmax and T1 / 2Ka of Example 6-4 of the present invention are not significantly different from those of Experimental Group II and Experimental Group III, indicating that this example does not change the peak time and elimination rate of doxycycline hydrochloride in broilers. However, the pharmacokinetic parameters Cmax and AUC of the present example are 0-∞Compared with experimental group II and experimental group III, the difference is significant, indicating that under the same dosage, the peak blood drug concentration and bioavailability of this embodiment are higher than those of experimental group II and experimental group III, thereby also proving that the doxycycline hydrochloride preparation of the present invention improves the stability of doxycycline hydrochloride in water when concentrated drinking water is used, and achieves very good results compared with existing preparations and technologies.
[0134] 3. Clinical efficacy trials
[0135] Clinical efficacy test was carried out in a white-feathered broiler farm in Xinzheng City, Henan Province. The experimental animals were 35-day-old white-feathered broilers, and respiratory symptoms appeared in the flocks, which were diagnosed as chronic respiratory diseases mainly caused by mycoplasma infection by clinical veterinary diagnosis. The flocks were randomly divided into 5 groups, 200 chickens in each group, the medicine used in experimental group I was the doxycycline hydrochloride preparation prepared by embodiment 6-4 of the present invention, the medicine used in experimental group II was the commercially available batch of doxycycline hydrochloride soluble powder (batch number: 2201013) of Shandong ** Pharmaceutical Co., Ltd., the medicine used in experimental group III was doxycycline hydrochloride non-aqueous solution (doxycycline hydrochloride non-aqueous solution preparation was prepared according to the preparation method of CN114732783A document record), experimental group 4 was a blank control group, and the above four groups of chickens were raised under the same environment. In terms of doxycycline hydrochloride, the three groups of group dosages were all 1200mg / L, and the mode of administration was concentrated 6h drinking water administration, continuous medication 5d, and the efficacy of each experimental group was statistically analyzed. The medication conditions of the four experimental groups are shown in Table 10, and the results of the clinical efficacy test are shown in Table 11.
[0136] The criteria for judging cure are: mental state and appetite return to normal after administration through drinking water during the trial, and there are no clinical symptoms such as coughing, sneezing, and mouth breathing.
[0137] The effective judgment standard is: the chickens' spirit, appetite and breathing have improved significantly after taking the medicine during the test period, but there are clinical symptoms.
[0138] Table 10 Grouping and medication of experimental animals
[0139]
[0140] Table 11 Clinical pharmacodynamics test results
[0141]
[0142] As shown in Table 11, the doxycycline hydrochloride preparation prepared by the present invention is significantly superior to the existing doxycycline hydrochloride preparation in terms of efficacy, cure rate and mortality rate, and has a good therapeutic effect on chronic respiratory diseases infected by Mycoplasma galli. It can be seen that after improving the stability of doxycycline hydrochloride in concentrated drinking water, the present invention has achieved a better clinical treatment effect than the existing preparations and technologies.
[0143] In summary, the above are only preferred embodiments of the present invention, and are not intended to limit the present invention in other forms. Any technician familiar with the profession may use the above technical content as inspiration to make changes or modifications. This is an equivalent embodiment of equivalent changes. However, any simple modification, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the technical concept of the present invention still fall within the scope of protection of the claims of the present invention.
Claims
1. A doxycycline hydrochloride preparation, characterized in that: The invention is prepared from doxycycline hydrochloride, a sunscreen, an oxygen inhibitor and an adsorption carrier, wherein the sunscreen is a plant essential oil with ultraviolet absorption function, and the oxygen inhibitor is an oily substance with antioxidant function; the density relationship between the sunscreen and the oxygen inhibitor is: sunscreen < oxygen inhibitor < water; the sunscreen is at least one of marigold oil, tangerine oil, grapefruit essential oil and lemon oil, and the oxygen inhibitor is at least one of VE oil, prickly ash oil, cinnamon oil and houttuynia cordata oil; the mass ratio of the doxycycline hydrochloride, the sunscreen, the oxygen inhibitor and the adsorption carrier is 1:0.1-0.5:0.1-0.5:1-3; and the adsorption carrier is β-cyclodextrin.
2. The doxycycline hydrochloride preparation according to claim 1, characterized in that The sunscreen is lemon oil, and the antioxidant is houttuynia cordata oil.
3. The doxycycline hydrochloride preparation according to claim 2, characterized in that: The limonene content in the lemon oil is ≥85%, and the total volatile oil in the houttuynia cordata oil is ≥80%.
4. A method for preparing the doxycycline hydrochloride preparation according to any one of claims 1 to 3, characterized in that: The following steps are involved: (1) dissolving a sunscreen and an oxygen inhibitor in a solvent to obtain a solution a; (2) The solution a is solidified and adsorbed by an adsorption carrier to obtain a powder b; the doxycycline hydrochloride and the powder b are evenly mixed to obtain a doxycycline hydrochloride preparation.
5. The preparation method according to claim 4, characterized in that: The solvent is ethanol.
6. Use of the doxycycline hydrochloride preparation according to any one of claims 1 to 3 in the preparation of veterinary drugs.
